학술논문
Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
Document Type
Journal Article
Author
Source
Internal Medicine. 2022, 61(11):1663
Subject
Language
English
ISSN
0918-2918
1349-7235
1349-7235
Abstract
Results The switch from mepolizumab to benralizumab caused a near-complete reduction in the eosinophil count (p=0.008). The annual rate of clinically relevant exacerbations and hospitalizations diminished as well, albeit with no statistical significance. We found no improvement in the lung function after switching treatment and no difference in the treatment response between the groups.